Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up

Table 1 Demographic and clinical characteristics of the study population

Clinical characteristics	IBD (CD + UC)	Crohn’s disease	Ulcerative colitis
n	50	40	10
Gender (M/F)	23/27	18/22	4/6
Age (yr)1	47.7 ± 15.6	45.4 ± 17.9	52.7 ± 8.9
Median disease duration (yr)	10.8	9.2	9.3
(range)	(0.3-22.2)	(0.3-22.2)	(2.1-15.1)
Disease activity (T0)1	N/A	245.0 ± 99.3 (CDAI)2	12.9 ± 2.8 (CAI)
Site of disease n (%):
Small bowel/pouch		13 (32.5)
Large bowel		4 (10)	10
Ileum-colon		23 (57.5)
Steroid therapy at enrolment (%) (≥ 0.7 mg/kg per day)	39 (78)	30 (75)	9 (90)
Concomitant medications n (%):
Salicylates	29	21 (52.5)	8 (80)
6-MP/azathioprine	31	28 (70)	3 (30)
Antibiotics	25	24 (60)	1 (10)

¹Mean ± SD;

²5 steroid-dependent patients had baseline Crohn's disease activity index (CDAI) < 150; CAI: Clinical activity index; T0: Baseline time; N/A: Not applicable.